Co-Authors
This is a "connection" page, showing publications co-authored by Luca Stingeni and Katharina Hansel.
Connection Strength
3.164
-
Dupilumab in adolescents with moderate to severe atopic dermatitis: a 32-week real-world experience during the COVID-19 pandemic. Clin Exp Dermatol. 2022 01; 47(1):165-167.
Score: 0.964
-
A multicenter study on effectiveness and safety of risankizumab in psoriasis: an Italian 16-week real-life experience during the COVID-19 pandemic. J Eur Acad Dermatol Venereol. 2021 Mar; 35(3):e169-e170.
Score: 0.912
-
Atopic dermatitis in adolescents: Effectiveness and safety of dupilumab in a 16-week real-life experience during the COVID-19 pandemic in Italy. Dermatol Ther. 2021 09; 34(5):e15035.
Score: 0.238
-
Severe adverse drug reaction in SARS-CoV-2 infection: AGEP induced by ceftriaxone and confirmed by patch test. Contact Dermatitis. 2021 09; 85(3):366-368.
Score: 0.235
-
Skin tests in urticaria/angioedema and flushing to Pfizer-BioNTech SARS-CoV-2 vaccine: Limits of intradermal testing. Allergy. 2021 08; 76(8):2605-2607.
Score: 0.235
-
Adverse cutaneous and mucous reactions from anti SARS-CoV-2 vaccines: recommendations from the Italian Society of Dermatology (SIDeMaST). Ital J Dermatol Venerol. 2021 Apr; 156(2):115-117.
Score: 0.234
-
SARS-CoV-2 vaccines and biological treatments: dermatological perspectives. Ital J Dermatol Venerol. 2021 Apr; 156(2):118-120.
Score: 0.234
-
Drug reaction with eosinophilia and systemic symptoms syndrome to hydroxychloroquine, an old drug in the spotlight in the COVID-19 era. Dermatol Ther. 2020 Jul; 33(4):e13499.
Score: 0.055
-
Dupilumab and COVID-19: What should we expect? Dermatol Ther. 2020 Jul; 33(4):e13502.
Score: 0.055